Levonorgestrel IUD for Uterine Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well levonorgestrel-releasing intrauterine system works in treating patients with complex atypical hyperplasia or grade I endometrial cancer. High levels of estrogen can cause the growth of endometrial cancer cells. Progesterone can help balance the amount of estrogen present. Hormone therapy using levonorgestrel, a type of progesterone, may fight endometrial cancer by helping regulate hormone levels.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for guidance.
Is the Levonorgestrel IUD generally safe for use in humans?
How does the Levonorgestrel-Releasing Intrauterine System differ from other treatments for uterine cancer?
The Levonorgestrel-Releasing Intrauterine System (LNG-IUD) is unique because it delivers hormones directly to the uterus, which can help treat early-stage uterine cancer and complex atypical hyperplasia while preserving fertility. Unlike systemic treatments, it provides localized hormone therapy, reducing the risk of side effects and potentially lowering the risk of developing endometrial cancer by up to 50%.13678
What data supports the effectiveness of the treatment Levonorgestrel-Releasing Intrauterine System for uterine cancer?
Research shows that the Levonorgestrel-Releasing Intrauterine System (LNG-IUS) can help manage early-stage endometrial cancer and atypical hyperplasia (a condition where the lining of the uterus becomes too thick) by improving endometrial thickness and pregnancy outcomes. It has also been used effectively in combination with other treatments to preserve fertility in young women with early endometrial cancer.3691011
Who Is on the Research Team?
Shannon N Westin
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with complex atypical hyperplasia or grade I endometrial cancer who haven't had prior treatments. It's suitable for those wanting to preserve fertility, have severe obesity, or significant other health issues. Exclusions include acute pelvic/liver disease, higher-grade cancers, current breast cancer/pregnancy/breastfeeding, uterine anomalies, and conditions increasing infection risk.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo placement of a levonorgestrel-releasing intrauterine system
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Levonorgestrel-Releasing Intrauterine System
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator